Does stopping Ozempic cause double the weight to come back?

What did @realdrbae actually say?

The core argument: GLP-1 medications suppress appetite, and stopping them removes that suppression, which lets old eating habits flood back. The creator also pushed back on the idea that the medication itself causes rebound weight gain, arguing there's "no evidence that the medication actually caused you to regain double your weight." The proposed solution was simple: don't stop taking it.

This is a condensed but mostly reasonable summary of how semaglutide works pharmacologically. The creator is responding to a specific claim from influencer Remi Bader, who said she gained double her starting weight after stopping Ozempic. That's a vivid personal story, and the creator correctly notes it doesn't constitute evidence that the drug caused the regain.

Does the science back this up?

On the core mechanism, yes. The appetite-suppression explanation holds up. But the "no evidence" framing on rebound weight gain is where things get slippery, because there's actually quite a bit of evidence that stopping GLP-1s leads to significant weight regain, even in people who changed their habits.

The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) followed participants one year after stopping semaglutide 2.4mg. On average, they regained two-thirds of the weight they had lost within 68 weeks. Critically, this happened even with continued lifestyle support. A separate analysis from the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar findings with tirzepatide: discontinuation led to substantial weight regain regardless of behavioral interventions. So the claim that the medication doesn't cause rebound is technically defensible on a semantic level, but it glosses over a real and well-documented pattern. The drug's absence, not the drug itself, drives regain. That distinction matters clinically, but it may feel like splitting hairs to patients.

What did they get wrong (or right)?

The creator gets credit for correctly explaining the appetite-suppression mechanism and for pushing back on the idea that Remi Bader's personal story is generalizable evidence. Those are fair and accurate points.

The part that needs pushback: saying there's "no evidence" of significant weight regain after stopping is misleading. The Wilding 2022 data is widely cited and unambiguous. A more honest framing would be: the medication doesn't cause rebound weight gain directly, but stopping it reliably removes the pharmacological brake on appetite, and for many people, behavioral changes alone aren't enough to compensate for that.

The advice to "continue the medication if it's working for you" is reasonable in context, but it skips over important realities:

• Long-term supply and insurance coverage remain inconsistent for many patients.
• Side effect burden varies, and some people cannot tolerate indefinite use.
• There are no 10-plus-year safety datasets yet for semaglutide at weight-management doses.

Recommending indefinite use without acknowledging those gaps is a bit too breezy for a medical professional speaking to 3 million viewers.

What should you actually know?

GLP-1 receptor agonists work while you take them. That's not a flaw, it's how most chronic disease medications work. Blood pressure drugs stop working when you stop taking them too. The problem is that obesity has historically been framed as a willpower issue, so the idea of indefinite medication use feels more loaded than it should.

What the research actually shows is that weight regain after stopping GLP-1s is common, substantial, and not fully preventable through diet and exercise alone for most people. Bader's reported experience of gaining "double the weight" is unusual enough that it warrants skepticism as a general claim, but the broader pattern of significant regain is well-supported. Patients deserve to hear that before they start, not after they stop.

If you are considering a GLP-1 medication, the honest conversation with your provider should include: what happens if you need to stop, whether your insurance covers long-term use, and what your plan looks like if supply issues arise. These are practical questions the video doesn't raise.